Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter ...

Shares of Hims & Hers Health ( HIMS 12.82%) surged on Tuesday, closing the session up 5.25% after having been up by as much ...

Hims & Hers Health, Inc. is anticipated to report earnings per share (EPS) of $0.11 for the current quarter, reflecting a substantial 120% increase from the same period last year. Revenue is projected ...

Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Hims & Hers Health shares closed up 5% on Tuesday after the company announced patients can access Eli Lilly's weight loss ...

Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Hims & Hers Health, Inc. (HIMS) closed the latest trading day at $27.23, indicating a +1.57% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of ...